Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Donald Trump
Fierce Pharma
Prasad exit signals more permissive FDA for cell and gene field
Prasad’s replacement is “likely to fall further along the ‘right-to-try’ arm of the MAHA-RFK policy side,” Leerink analyst Mani Foroohar said.
Angus Liu
Jul 31, 2025 9:10am
FDA delays hit clinical trial launch decisions
Jul 30, 2025 10:29am
Fierce Pharma
New US-EU trade deal includes 15% tariffs on pharmaceuticals
Jul 29, 2025 10:34am
Fierce Pharma
AZ reveals plan for huge site in Virginia, part of $50B US outlay
Jul 22, 2025 7:45am
UK puts down $335M for new pandemic preparedness research center
Jul 17, 2025 1:09pm
Fierce Healthcare
HHS resumes mass layoffs after Supreme Court reopens floodgates
Jul 15, 2025 3:00pm